Article · 13 Feb 2026
Conference abstractPublished 3 Aug 2015
Key issues with amended CBE-supplementation for ANDA holders
Touro College of Pharmacy, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
FDAâÂ?Â?s proposed rule to amend the regulations would allow generic manufacturers to change their productsâÂ?Â? labeling to reflect newly acquired safety information in advance of FDAâÂ?Â?s review of the change; i.e. changes-being-effected (CBE-0) procedures. Currently, ANDA holders may not use the CBE-0 process to unilaterally change ANDA labeling in a manner that differs from the Reference Listed Drug (RLD). FDAâÂ?Â?s proposal comes about, in part, because of two recent U.S. Supreme Court decisions. In 2011, in Pliva Inc. v. Mensing the Court held that injured plaintiffsâÂ?Â? state-law failure to warn claims against generic manufacturers are pre-empted under federal law. In 2013, in Mut. Pharm Co. Inc. v. Bartlettthe Court held that injured plaintiffsâÂ?Â? state-law design defect claims against generic manufacturers that turn on the adequacy of a drugâÂ?Â?s warnings are also preempted by federal law. In the aftermath of these two decisions, consumers injured by generic drugs are left without recourse. Proponents of FDAâÂ?Â?s proposed ruleargue that it will provide an avenue to file failure-to-warn tort claims against generic manufacturers and encouraging them to establish extensive drug safety systems to protect the public while creating parity among application holders. Opponents argue that the proposed rule violates FDAs statutory mandate, would increase generic drug prices (and potential shortages), and rather than promoting safety would lead to confusion when labeling for a generic version of a medication will not be the same as labeling for the underlying brand-name drug. The proposed rule would create a regulatory framework whereby multiple different warnings can simultaneously exist in the marketplace for multiple generic versions of a drug. Opponents also argue the billions of dollars that will be diverted to the legal system by consumer plaintiffs could better be devoted to healthcare improvements. Other advocate that in as much as an absence of evidence exists to indicate that current authority of brand manufacturers to make temporary labeling changes upon submission of a CBE-0 supplement has led to improved patient safety, the current policy should be re-evaluated. FDA may proceed with a final proposed rule, which generic manufacturers have vowed to legally challenge or legislation may be proposed.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Martha”

